CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL
Condition: B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma Intervention: Biological: anti-CD19 UCAR-T injection Sponsors: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China; Gracell Biotechnology Shanghai Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biotechnology | China Health | Hospitals | Leukemia | Lymphoma | Research